These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29911955)

  • 1. Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy.
    Roberts MH; Takeda MY; Kindilien S; Barqawi YK; Borrego ME
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):487-503. PubMed ID: 29911955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.
    Connock M; Frew E; Evans BW; Bryan S; Cummins C; Fry-Smith A; Li Wan Po A; Sandercock J
    Health Technol Assess; 2006 Mar; 10(7):iii, ix-118. PubMed ID: 16545206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland.
    Väätäinen S; Soini E; Peltola J; Charokopou M; Taiha M; Kälviäinen R
    Adv Ther; 2020 Jan; 37(1):477-500. PubMed ID: 31808053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective.
    Tremblay G; Howard D; Tsong W; Patel V; De Rosendo J
    Epilepsy Behav; 2018 Sep; 86():108-115. PubMed ID: 30001911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
    Geitona M; Stamuli E; Giannakodimos S; Kimiskidis VK; Kountouris V; Charokopou M; Christou P
    J Med Econ; 2019 Apr; 22(4):359-364. PubMed ID: 30652931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of epileptic surgery compared with medical treatment in children with drug-resistant epilepsy.
    Catchpool M; Dalziel K; Mahardya RTK; Harvey AS
    Epilepsy Behav; 2019 Aug; 97():253-259. PubMed ID: 31254845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side-effects of antiepileptic drugs: the economic burden.
    de Kinderen RJ; Evers SM; Rinkens R; Postulart D; Vader CI; Majoie MH; Aldenkamp AP
    Seizure; 2014 Mar; 23(3):184-90. PubMed ID: 24315662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use.
    Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS
    Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations.
    Elliott J; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
    Syst Rev; 2019 Mar; 8(1):75. PubMed ID: 30917869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries.
    Heaney DC; Shorvon SD; Sander JW; Boon P; Komarek V; Marusic P; Dravet C; Perucca E; Majkowski J; Lima JL; Arroyo S; Tomson T; Ried S; van Donselaar C; Eskazan E; Peeters P; Carita P; Tjong-a-Hung I; Myon E; Taieb C
    Epilepsia; 2000; 41 Suppl 5():S37-44. PubMed ID: 11045437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).
    Balabanova S; Taylor C; Sills G; Burnside G; Plumpton C; Smith PEM; Appleton R; Leach JP; Johnson M; Baker G; Pirmohamed M; Hughes DA; Williamson PR; Tudur-Smith C; Marson AG
    BMJ Open; 2020 Aug; 10(8):e040635. PubMed ID: 32847927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
    Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011412. PubMed ID: 28661008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
    Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011412. PubMed ID: 29243813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epilepsy in adults: a costs-of-illness study].
    Vlasov PK; Orekhova NV; Filatova NV; Leonova MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):44-7. PubMed ID: 20873473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.